Showing 1911-1920 of 2123 results for "".
- Risdiplam Has Long-Term Efficacy and Safety in Treatment of Spinal Muscular Atrophyhttps://practicalneurology.com/news/risdiplam-has-long-term-efficacy-and-safety-in-treatment-of-spinal-muscular-atrophy/2469854/New clinical trial data for risdiplam (Evrysdi; Genentech, San Franscisco, CA) shows long-term efficacy and safety of risdiplam for up to 3 years of treatment of spinal muscular atrophy (SMA). These data come from a broad population of people with SMA2 and SMA3. In the SUNFISH stu
- Blarcamesine Treatment Shows Clinical and Biomarker Improvements in Parkinson Disease Dementiahttps://practicalneurology.com/news/blarcamesine-treatment-shows-clinical-and-biomarker-improvements-in-parkinson-disease-dementia/2469852/In a clinical trial (NCT03774459) of blacarmesine (Anavex 2-73; Anavex Life Sciences, New York, NY) for Parkinson disease dementia (PDD), clinical improvements in motor and nonmotor symptoms were seen. There was also evidence of releva
- Early Presymptomatic Treatment With Nusinersen Results Show Continued Increases in Meeting Motor Milestoneshttps://practicalneurology.com/news/early-presymptomatic-treatment-with-nusinersin-results-show-continued-increases-in-meeting-motor-milestones/2469850/Results from the NURTURE study (NCT02386553) show presymptomatic infants with spinal muscular atrophy (SMA) treated with nusinersen (Spinraza; Biogen, Cambridge MA) for up to 5.7 years (median 4.9 years) continue gaining motor function
- Atogepant Significantly Reduced Monthly Migraine Days for Chronic Migrainehttps://practicalneurology.com/news/atogepant-significantly-reduced-monthly-migraine-days-for-chronic-migraine/2469846/Atogepant (Quliptatm; AbbVie, North Chicago, IL), 60 mg once daily or 30 mg twice daily , significantly reduced monthly migraine days (MMD) compared with placebo in phase 3 trial (NCT03855137) for adults with chronic migraine. Participants (n=778) who had at least a 1-year of chronic
- Study to Assess Impact of Lifestyle Interventions to Control Epileptic Seizureshttps://practicalneurology.com/news/study-to-assess-impact-of-lifestyle-interventions-to-control-epileptic-seizures/2469839/An innovative study has launched to evaluate a possible link between epilepsy and stress. The 5-year clinical trial is the first to compare the effect of lifestyle interventions on seizure control. The study will enroll 1,000 participants with difficult-to-treat epilepsy, observe the im
- Risk-Benefit Profile of Ozanimod for Multiple Sclerosis Did Not Change With COVID-19https://practicalneurology.com/news/risk-benefit-profile-of-ozanimod-for-multiple-sclerosis-did-not-change-with-covid-19/2469834/In the open-label extension DAYBREAK study (NCT02576717) among participants in 4 clinical trials of ozanimod (Zeposia; Bristol Myers Squibb, New York, NY) for multiple sclerosis (MS), the effect of COVID-19 was evaluated. The 2,494 par
- Blarcamesine Reduces Rett Syndrome Symptomshttps://practicalneurology.com/news/blarcamesine-reduces-rett-syndrome-symptoms/2469814/Blarcamesine (Anavex2-73; Anavex Life Sciences Corp, New York, NY), once daily oral liquid doses of up to 30mg, demonstrated statistically significant reductions in Rett syndrome symptoms with related changes in potential biomarkers, GABA and L-Alpha-aminoadipic acid (L-AAA), of disease pathology
- Tic Development Not Associated With Strep in Children of Parents With Chronic Tic Disordershttps://practicalneurology.com/news/tics-development/2469813/A study published in Neurology found there was no link between a strep throat infection and the development of tics in children who have a parent or sibling with a chronic tic disorder. In the study, 24% of the children (n=61) developed tics. At 2-year follow up assessments, 7 more chil
- Byrostatin Improves Cognition in Advanced Alzheimer Diseasehttps://practicalneurology.com/news/byrostatin-improves-cognition-in-advanced-alzheimer-disease/2469812/An article published in the Journal of Alzheimer Disease provides evidence from 2 placebo-controlled trials that bryostatin (DB11752; Synaptogenix Inc., New York, NY) improved cognition from baseline in individuals with advanced Alzheimer disea
- A New Phase 2 Trial of Tominersen for Early Huntington Disease Designedhttps://practicalneurology.com/news/a-new-phase-2-trial-of-tominersen-for-early-huntington-disease-designed/2469801/A new phase 2 trial is planned to evaluate tominersen (IONIS-HTTRx; Ionis Pharmaceuticals, Carlsbad, CA) to treat early-stage Huntington disease (HD). Although the phase 3 GENERATION HD1 trial of tominersen for HD was halted, post hoc analyses suggest tominersen may benefit younger adults with lo